125 related articles for article (PubMed ID: 21106451)
41. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
[TBL] [Abstract][Full Text] [Related]
43. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity.
Feng WF; Zhao YB; Huang W; Yang YZ
J Enzyme Inhib Med Chem; 2010 Aug; 25(4):459-66. PubMed ID: 19951006
[TBL] [Abstract][Full Text] [Related]
44. Novel methods and strategies in the discovery of TACE inhibitors.
Murumkar PR; Giridhar R; Yadav MR
Expert Opin Drug Discov; 2013 Feb; 8(2):157-81. PubMed ID: 23231541
[TBL] [Abstract][Full Text] [Related]
45. Prediction of novel and selective TNF-alpha converting enzyme (TACE) inhibitors and characterization of correlative molecular descriptors by machine learning approaches.
Cong Y; Yang XG; Lv W; Xue Y
J Mol Graph Model; 2009 Oct; 28(3):236-44. PubMed ID: 19729328
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.
Park K; Gopalsamy A; Aplasca A; Ellingboe JW; Xu W; Zhang Y; Levin JI
Bioorg Med Chem; 2009 Jun; 17(11):3857-65. PubMed ID: 19410464
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.
Gilmore JL; King BW; Asakawa N; Harrison K; Tebben A; Sheppeck JE; Liu RQ; Covington M; Duan JJ
Bioorg Med Chem Lett; 2007 Aug; 17(16):4678-82. PubMed ID: 17576061
[TBL] [Abstract][Full Text] [Related]
48. Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
Levin JI; Chen JM; Laakso LM; Du M; Du X; Venkatesan AM; Sandanayaka V; Zask A; Xu J; Xu W; Zhang Y; Skotnicki JS
Bioorg Med Chem Lett; 2005 Oct; 15(19):4345-9. PubMed ID: 16084720
[TBL] [Abstract][Full Text] [Related]
49. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
[TBL] [Abstract][Full Text] [Related]
50. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
51. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Yang A; Chen XT; Xue CB; Roderick J; Liu RQ; Covington MB; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1413-7. PubMed ID: 17188863
[TBL] [Abstract][Full Text] [Related]
52. Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.
Yang JS; Chun K; Park JE; Cho M; Seo J; Song D; Yoon H; Park CH; Joe BY; Choi JH; Kim MH; Han G
Bioorg Med Chem; 2010 Dec; 18(24):8618-29. PubMed ID: 21078557
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.
Xue CB; Chen XT; He X; Roderick J; Corbett RL; Ghavimi B; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Trzaskos J; Newton RC; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2004 Sep; 14(17):4453-9. PubMed ID: 15357971
[TBL] [Abstract][Full Text] [Related]
54. TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats.
Tang ZY; Loss G; Carmody I; Cohen AJ
Transplantation; 2006 Dec; 82(11):1518-23. PubMed ID: 17164725
[TBL] [Abstract][Full Text] [Related]
55. IK682, a tight binding inhibitor of TACE.
Niu X; Umland S; Ingram R; Beyer BM; Liu YH; Sun J; Lundell D; Orth P
Arch Biochem Biophys; 2006 Jul; 451(1):43-50. PubMed ID: 16762314
[TBL] [Abstract][Full Text] [Related]
56. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1.
Canault M; Leroyer AS; Peiretti F; Lesèche G; Tedgui A; Bonardo B; Alessi MC; Boulanger CM; Nalbone G
Am J Pathol; 2007 Nov; 171(5):1713-23. PubMed ID: 17872973
[TBL] [Abstract][Full Text] [Related]
57. [Screening of TACE peptide inhibitors from a phage display random 15-peptide library by recombinant TACE ecotodomain].
Huang W; Li LB; Han L; Zhang H; Yang YZ
Sheng Wu Gong Cheng Xue Bao; 2005 Jan; 21(1):30-5. PubMed ID: 15859325
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation.
Trifilieff A; Walker C; Keller T; Kottirsch G; Neumann U
Br J Pharmacol; 2002 Apr; 135(7):1655-64. PubMed ID: 11934805
[TBL] [Abstract][Full Text] [Related]
59. Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.
Park K; Aplasca A; Du MT; Sun L; Zhu Y; Zhang Y; Levin JI
Bioorg Med Chem Lett; 2006 Aug; 16(15):3927-31. PubMed ID: 16723229
[TBL] [Abstract][Full Text] [Related]
60. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock.
Horiuchi K; Kimura T; Miyamoto T; Takaishi H; Okada Y; Toyama Y; Blobel CP
J Immunol; 2007 Sep; 179(5):2686-9. PubMed ID: 17709479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
